FDA to review Neupogen biosimilar

Share this article:

Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar. Amgen's Neupogen patent lapsed in December.

The branded biologic has wrangled close to $4 billion in sales between 2011 and 2013, but the performance has not been because of a competition-free bubble: Neupogen already competes with Amgen's Neulasta, which has less-frequent dosing and a patent which runs into 2015. It also competes against Sandoz's lookalike drug, which is already in 40 countries where it is known as Zarzio.

Sandoz said in its 2013 annual report that Zarzio was the first biosimilar to “overtake its reference product,” an achievement coupled with Zarzio being the first to push Chugai's Granocyte from its market leader position.

Sandoz submitted its application through a process included in the FDA's 2009 Biologics Price Competition and Innovation Act.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.